Zacks Investment Research·19h ago
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes CareDexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
Abbott Laboratories is currently navigating a complex transition characterized by robust 7.8% year-over-year revenue growth in 2026Q1, yet this expansion is increasingly reliant on aggressive inorganic strategies that have elevated goodwill to $35.2 billion. W...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth reached 7.8% in 2026Q1, supported by a gross margin expansion to 56.3% from 50.4% in 2024Q1, though operating margins remain constrained between 13.9% and 19.6%.
The successful integration of Exact Sciences is expected to significantly boost Abbott's diagnostics business and overall growth trajectory.
Analysts project mid-teens growth for Cologuard, supported by a substantial addressable market.
New electrophysiology products like Volt PFA and TactiFlex Duo are receiving extremely favorable physician feedback, indicating potential for accelerated growth.
The Nutrition segment has faced declines due to incomplete pricing pass-through at retail, posing a risk to revenue.
The Exact Sciences acquisition is expected to dilute EPS, impacting earnings through 2026 and 2027 before becoming accretive.
Abbott faces litigation risks, including a recent $70 million jury award related to infant formula safety, with hundreds of similar cases pending.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 16, 2026 | $1.31+2.3% vs $1.28 | $12.6B+0.6% vs $12.5B |
Q2 2026 Apr 16, 2026 | $1.15+0.9% vs $1.14 | $11.2B+1.5% vs $11.0B |
Q1 2026 Jan 22, 2026 | $1.50+0.0% vs $1.50 | $11.5B-2.9% vs $11.8B |
Q4 2025 Oct 15, 2025 | $1.30+0.0% vs $1.30 | $11.4B-0.2% vs $11.4B |
Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.
ABT, CORT, PGEN and BHC offer low-beta healthcare exposure as rate-hike fears and market volatility persist.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Stocks clawed back from a wild Thursday session, oil surged past $100, and Wall Street analysts reshuffled their bets on names from Airbnb to Northrop Grumman. Find out which stocks got upgraded, downgraded, or newly covered heading into the first Friday of Q4 2026.
Benchmark ABT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Abbott Laboratories (ABT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $97.50 | $169.83B | 26.21 | 5.67% | 14.72% | 12.96% | 2.42% | |
| $86.38 | $110.9B | 23.16 | 8.43% | 13.93% | 10.51% | — | |
| $42.60 | $63.32B | 21.96 | 19.87% | 17.47% | 14.76% | — | |
| $176.80 | $48.72B | 30.33 | 8.23% | 4.52% | 3.79% | — | |
| $23.49 | $12.13B | -13.42 | 5.72% | -9.27% | -16.67% | — | |
| $85.15 | $49.03B | 46.53 | 11.55% | 15.43% | 9.66% | — |
Abbott Laboratories (ABT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Abbott Laboratories (ABT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 16, 2026·SEC
Apr 27, 2026·SEC
Apr 17, 2026·SEC
Get notified when ABT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Abbott Laboratories (ABT) stock FAQ — growth, dividends, profitability & financials explained
Abbott Laboratories (ABT) reported $45.13B in revenue for fiscal year 2025. This represents a 310% increase from $11.01B in 1996.
Abbott Laboratories (ABT) grew revenue by 5.7% over the past year. This is steady growth.
Yes, Abbott Laboratories (ABT) is profitable, generating $6.28B in net income for fiscal year 2025 (14.7% net margin).
Yes, Abbott Laboratories (ABT) pays a dividend with a yield of 2.42%. This makes it attractive for income-focused investors.
Abbott Laboratories (ABT) has a return on equity (ROE) of 13.0%. This is reasonable for most industries.
Abbott Laboratories (ABT) generated $7.38B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
